By Ted Bosworth
By accurately assessing minimal residual disease (MRD) status, next-generation sequencing (NGS) is showing promise for improving the risk stratification of pediatric patients with newly diagnosed acute lymphoblastic leukemia (ALL), according to a multicenter study (abstract 618) presented at the 2021 annual meeting of the American Society of Hematology (ASH).
Unlike current assays such as flow cytometry (FCM), NGS assays employ unique genetic sequences in leukemia cells “to